Miscellaneous

What is Omidria used for?

Contents

What is Omidria used for?

Omidria® is added to an ocular irrigating solution used during cataract surgery or intraocular lens replacement and is indicated for maintaining pupil size by preventing intraoperative miosis and reducing postoperative ocular pain. Omidria must be diluted prior to intraocular use.

Does Medicare cover Omidria?

In addition to reducing patient exposure to opioids, CMS’ decision continues to provide important access to OMIDRIA for Medicare beneficiaries and to allow ophthalmic surgeons to use their best medical judgment to treat those patients. OMIDRIA is approved for use in both adults and children.

How much does Omidria cost?

The cost for Omidria intraocular solution (0.3%-1%) is around $1,951 for a supply of 16 milliliters, depending on the pharmacy you visit. Prices are for cash paying customers only and are not valid with insurance plans.

What is Trimoxi?

Trimoxi is a major breakthrough in reducing patient cost, inconvenience and post-operative complications. Trimoxi is a combination of steroid (triamcinolone) and antibiotic (moxifloxacin) that is placed into the vitreous after the IOL is inserted.

When was Omidria FDA approved?

Development Timeline for Omidria

Date Article
Dec 12, 2017 Approval Omeros Corporation Announces FDA Approval of Omidria for Use in Pediatric Patients
Jun 2, 2014 Approval FDA Approves Omidria for Use in Cataract and Other Intraocular Lens Replacement Procedures

What is Narsoplimab?

Narsoplimab is a human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2), the effector enzyme of the lectin pathway of the complement system. The lectin pathway is one of the principal pathways of complement and is activated primarily by tissue damage and microbial infection.

What happens if you don’t use the drops after cataract surgery?

If someone didn’t use their eye drops the best-case scenario would be that their eyes would take longer to heal, and may develop some scarring tissue. The worst-case scenario would be an infection – one that could end in loss of eyesight if not caught quickly.

Who makes Omidria?

Omeros Corporation
SEATTLE, June 2, 2014–Omeros Corporation OMER +8.64% today announced that the U.S. Food and Drug Administration (FDA) has approved Omidria™ (phenylephrine and ketorolac injection) 1%/0.3% for use during cataract surgery or intraocular lens replacement (ILR) to maintain pupil size by preventing intraoperative miosis ( …

What type of drug is Narsoplimab?

Narsoplimab: Our first-in-class monoclonal antibody complement inhibitor. Narsoplimab, also known as OMS721, is a fully human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2), the effector enzyme of the lectin pathway of the complement system.

Where to find the full information on omidria?

Please see the Full Prescribing Information for OMIDRIA. You are encouraged to report Suspected Adverse Reactions to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

When to use omidria with high blood pressure?

Systemic exposure of phenylephrine may cause elevations in blood pressure. Use OMIDRIA with caution in individuals who have previously exhibited sensitivities to acetylsalicylic acid, phenylacetic acid derivatives, and other nonsteroidal anti-inflammatory drugs (NSAIDs), or have a past medical history of asthma.

How is omidria used in cataract surgery?

OMIDRIA is a first-of-kind drug approved both in the US and in Europe to prevent miosis in cataract surgery and to reduce postoperative pain. OMIDRIA has been shown to reduce complications, to prevent intraoperative floppy iris syndrome (IFIS), and to reduce the need for opioids, pupil-expansion devices and postoperative steroids.

What are the inactive ingredients in omidria injection?

Inactive ingredients: citric acid monohydrate; sodium citrate dihydrate; water for injection; may include sodium hydroxide and/or hydrochloric acid for pH adjustment. Omidria is manufactured by Seattle-based biopharmaceutical company Omeros Corporation.